Searched for
CIPLA FINANCIAL PERFORMANCE
Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Q4 earnings review: Motilal Oswal highlights broad-based beat on estimates, lists 6 sectors that exceeded expectationsMotilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...
- Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Rising bond yields, oil prices keeping markets on edge; selective bets still emerging: Pankaj PandeyGlobal markets are under pressure due to rising bond yields and geopolitical tensions. Higher crude oil prices are a key concern, potential...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Cipla shares rally 6% in 2 days as Q1 results impress; brokerages raise target up to Rs 1,875Cipla shares: Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates re...
- Cipla shares surge over 6% post Q4 results. Should you buy or sell?Meanwhile, EBITDA for the quarter under review increased 13% YoY to Rs 1,316 crore as against 1166 crore in the last year period.
- Cipla eyes acquisitions, inorganic partnerships in US marketCipla plans acquisitions and inorganic partnerships in the US market while strengthening its presence in the domestic market. The company a...
- Fundamental Radar: Why is Cipla a top pick in the pharma space for Motilal Oswal? Sneha Poddar explainsOn the India business front, in particular, Cipla is working to not only enhance its prescription base but also strengthen its trade generi...
- Cipla to acquire South Africa-based Actor PharmaActor was founded in 2009 and has quickly grown to become the fifth largest privately owned OTC player in the South African market. Actor s...
- Buy Cipla, target price Rs 1110: Prabhudas LilladherCipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 81586.39 Crore) operating in Pharmaceuticals s...
- Buy Cipla, target price Rs 975: ICICI DirectCipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 73903.56 Crore) operating in Pharmaceuticals s...
- Cipla Q3 preview: Consolidated PAT seen rising 76% YoY aided by strong India, US opsAnalysts expect Cipla to report a consolidated net profit of Rs 616.8 crore on net sales of Rs 5,003 crore, according to estimates from six...
- In pharma, only the fittest will ride the crestThree leading pharma companies announced their June quarter results towards the end of the week — each with different levels of performance...
- Analysis: A tale of three pharma companies and a quarterCipla beat expectations riding the demand for Covid medication. The Street is likely to push the stock to its record high hit in 2015. Whil...
- Cipla settles over 6 pc higher on boursesShares of drug major Cipla today gained over 6 per cent after the company reported 17.47 per cent increase in net profit for the July-Septe...
- Cipla: Move to enter biotech looks opportuneCipla’s latest move to grow through acquisitions comes at a time when the company has been growing at lower than the industry growth rate f...
- Hold Cipla for target of Rs 252: KR ChokseyIn its results update on pharmaceutical major Cipla, brokerage KR Choksey has advised investors to Hold the stock for a price target of Rs ...
Load More
